In a surprise move Tuesday, the FDA rejected Orexigen’s proposed new diet drug Contrave, saying the company needed to run another study of its cardiovascular risks. With this rejection, all three of a slate of similar diet drug…
After the U.S. Food and Drug Administration rejected two other weight-loss pills earlier this year, an advisory panel has recommended the approval of Orexigen Therapeutics’s Contrave. If the FDA follows the recommendation, Cont…
Vivus shares are soaring this morning, even though the U.S. Food and Drug Administration rejected the drugmaker’s obesity drug Qnexa yesterday. Investors are hoping that the FDA’s rejection, which includes a request for more sa…
Drug and medical-device maker Abbott Laboratories announced Friday that it will voluntarily withdraw its controversial obesity drug Meridia, (sibutramine) from the U.S. market at the request of the FDA, due to concerns it incr…